BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene Ltd.

Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $7.00. Messer covers the Healthcare s...

Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)

RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $3.50. According to TipRanks, M...

Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital

Analysts fell to the sidelines weighing in on Avadel Pharmaceuticals (AVDL – Research Report) and Oncolytics Biotech (ONCY – Research Report) with ...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)

Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an update. Onco-Innovations Limited has announced a collaboration with Kuano Ltd. to accelerate ...

Onco-Innovations Partners with Kuano to Enhance PNKP Inhibitor Development

RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines yesterday and set a price target of $408.00. The company’s shares cl...

RBC Capital Remains a Buy on BeOne Medicines (ONC)

Zymeworks ($ZYME) stock rallied 29% on Monday, after the clinical-stage biotechnology company announced positive Phase 3 trial results for its gast...

Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets

The latest update is out from Oncolytics Biotech ( ($ONCY) ). Oncolytics Biotech Inc. has established a Gastrointestinal Tumor Scientific Advisory ...

Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers

Saudi Arabia’s Public Investment Fund, known as the PIF, has further trimmed its holdings of many of its U.S. stock positions in the third quarter....

Saudi Public Investment Fund Sells Major U.S. Stocks as Portfolio Value Falls in Third Quarter

Loncor Gold ( ($TSE:LN) ) has issued an announcement. Loncor Gold Inc. has announced a special shareholders’ meeting to approve a proposed arrangem...

Loncor Gold Calls Shareholders’ Meeting for Acquisition Approval

Citi analyst maintained a Buy rating on BeiGene Ltd on November 7 and set a price target of HK$243.00. The company’s shares closed yesterday at HK$...

Citi Sticks to Its Buy Rating for BeiGene Ltd (6160)

In a report released on November 7, from UOB Kay Hian maintained a Buy rating on BeiGene Ltd, with a price target of HK$252.00. The company’s share...

BeiGene Ltd (6160) Gets a Buy from UOB Kay Hian

In a report released on November 7, from Bank of America Securities maintained a Buy rating on BeiGene Ltd, with a price target of HK$242.87. The c...

Bank of America Securities Sticks to Their Buy Rating for BeiGene Ltd (6160)

In a report released today, Gena Wang from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $385.00. Wang covers the Hea...

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

CLSA analyst Matthew Yan maintained a Buy rating on BeiGene Ltd on November 7 and set a price target of HK$288.00. The company’s shares closed last...

CLSA Reaffirms Their Buy Rating on BeiGene Ltd (6160)

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides AB reported a significant growth in net sales for Q3 2025, with a 174% incr...

Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones

Onco-Innovations Ltd. ( ($TSE:ONCO) ) just unveiled an update. Onco-Innovations Limited has outlined its strategic objectives for the upcoming year...

Onco-Innovations Outlines Strategic Objectives and U.S. Expansion Plans

An update from Onco-Innovations Ltd. ( ($TSE:ONCO) ) is now available. Onco-Innovations Limited has appointed Jared Rushton to its Board of Directo...

Onco-Innovations Strengthens Board and Boosts Marketing Efforts

Citi analyst Thomas Chauvet maintained a Buy rating on Moncler S.p.A. today and set a price target of €59.00. The company’s shares closed yesterday...

Moncler S.p.A. (0QII) Receives a Buy from Citi

In a report released yesterday, Nick Anderson CFA from Berenberg Bank maintained a Hold rating on Moncler S.p.A., with a price target of €55.00. Th...

Moncler S.p.A. (0QII) Receives a Hold from Berenberg Bank

In a report released yesterday, Piral Dadhania from RBC Capital maintained a Hold rating on Moncler S.p.A., with a price target of €53.00. The comp...

Moncler S.p.A. (0QII) Receives a Hold from RBC Capital

Onconetix ( ($ONCO) ) just unveiled an announcement. On October 23, 2025, Onconetix, Inc.’s Board of Directors decided to hold the 2025 annual meet...

Onconetix Announces 2025 Annual Meeting Details

In a report released today, Edouard Aubin from Morgan Stanley maintained a Hold rating on Moncler S.p.A., with a price target of €51.00. The compan...

Moncler S.p.A. (0QII) Gets a Hold from Morgan Stanley

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines is conducting a Phase 1a/1b clinical ...

BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?

In a report released today, James Grzinic from Jefferies maintained a Hold rating on Moncler S.p.A., with a price target of €49.00. The company’s s...

Jefferies Sticks to Its Hold Rating for Moncler S.p.A. (0QII)

Loncor Gold ( ($TSE:LN) ) has shared an update. On October 14, 2025, Loncor Gold Inc. announced its acquisition by Chengtun Mining Group Co., Ltd. ...

Loncor Gold Acquired by Chengtun Mining for C$261 Million

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines is conducting a Phase 1 clinical stud...

BeOne Medicines’ New Study on Drug Bioavailability and Food Effects

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1/2, Open-Label, Do...

BeiGene’s BGB-16673 Study: A New Hope for B-Cell Malignancies?

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines (ONC) is conducting a Phase 2 study t...

BeOne Medicines’ Tislelizumab Study: A Potential Game-Changer for MSI-H/dMMR Tumors

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines is conducting a Phase 2 clinical stud...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ONC	$347.72	-0.45%	163.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ONC	$347.72	-0.4%	163.48K
3
4
5
6

ONC

ONC

Dividend Overview

Get BeiGene Ltd. Data in Excel

Get BeiGene Ltd. Data in Excel